The challenge of systemic immunoglobulin light-chain amyloidosis (Al).

Giovanni Palladini, Raymond L. Comenzo

Research output: Contribution to journalArticlepeer-review


The cardiac involvement and associated mortality that occur in systemic AL amyloidosis remain among the most challenging aspects of the systemic amyloid-related diseases. Monoclonal immunoglobulin light chains produced by a clone of plasma cells are usually the cause of symptoms and organ dysfunction via both poorly understood toxic effects of misfolded species and accumulation of interstitial amyloid fibrils in key viscera. Treatment is aimed at eliminating the clonal cells in order to eliminate toxic light chain production. Recent advances in therapy have helped many patients with AL achieve complete hematologic responses and significant reversal of organ damage but these benefits do not extend to that 10-15 % who present with advanced cardiac involvement. Even with cardiac transplant followed by effective therapy such as stem cell transplant, outcomes for these patients remain promising at best.

Original languageEnglish
Pages (from-to)609-642
Number of pages34
JournalSub-Cellular Biochemistry
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The challenge of systemic immunoglobulin light-chain amyloidosis (Al).'. Together they form a unique fingerprint.

Cite this